GlassScriptPhysician profile
Angela Opal Allen
NPI 1740882117
$3,075.44
in general payments reported to CMS, 2019-2025
32 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.66 · 2022: $198 · 2023: $672 · 2024: $1,146 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,821.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $497.30 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $459.84 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $362.09 | 2022-2025 | |
| Glaxosmithkline, LLC. | $228.26 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $168.07 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.94 | 2021-2024 | Caplyta |
| Alkermes, INC. | $130.20 | 2021-2023 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $120.98 | 2024 | Austedo Xr |
| Lilly USA, LLC | $112.77 | 2022-2024 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $107.82 | 2023-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $96.38 | 2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $78.89 | 2023-2024 | Hetlioz, Fanapt |
| Idorsia Pharmaceuticals US INC | $74.30 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.52 | 2023-2024 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $63.69 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $41.02 | 2025 | Belbuca, Xtampza |
| Uswm, LLC | $39.72 | 2023 | Lucemyra, Zimhi |
| Abiomed | $34.49 | 2024 | Impella |
| Bioxcel Therapeutics, INC. | $25.00 | 2023 | Igalmi |
| Eisai INC. | $20.86 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $19.60 | 2023 | Abilify Asimtufii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.83 | 2022 | |
| Sk Life Science, INC. | $18.02 | 2024 | |
| Globus Medical, INC. | $17.70 | 2025 | Omnia |
| Astellas Pharma US INC | $16.87 | 2024 | Veozah |
| Azurity Pharmaceuticals, INC. | $16.81 | 2023 | Horizant |
| Neurocrine Biosciences, INC. | $16.28 | 2022 | |
| Fisher & Paykel Healthcare INC | $16.26 | 2025 | Fisher & Paykel Healthcare |
| Dynavax Technologies Corporation | $15.32 | 2024 | Heplisav-B |
| Orexo US, INC. | $15.18 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.50 | 2023 | Seglentis |
| Currax Pharmaceuticals LLC | $12.93 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.